Brett J Theeler1, Benjamin Ellezam1, Zsila S Sadighi1, Vidya Mehta1, M Diep Tran1, Adekunle M Adesina1, Janet M Bruner1, Vinay K Puduvalli1. 1. Department of Neurology and John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland (B.J.T.); Department of Pathology; CHU Sainte-Justine, Universite de Montreal, Montréal Quebec, Canada (B.E.); Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee (Z.S.S.); Department of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas (V.M., M.D.T., A.M.A.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (J.M.B.); Department of Neurosurgery, The Ohio State University Arthur G. James Cancer Hospital, Columbus, Ohio (V.K.P.).
Abstract
BACKGROUND: Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution. METHODS: We identified 127 adult PAs in our institutional database. Cases with available tissue were tested for BRAF-KIAA1549 fusion/duplication (B-K fusion) by fluorescence in situ hybridization and submitted for mutation profiling using the Sequenom mutation profiling panel. Subgroup analyses were performed based on clinical and molecular data. RESULTS: The majority of adult PAs are supratentorial. Twenty-two percent of cases had an initial pathologic diagnosis discordant with the diagnosis made at our institution. Recurrence was seen in 42% of cases, and 13% of patients died during follow-up. Adjuvant radiotherapy following surgical resection was associated with a statistically significant decrease in progression-free survival (P = .004). B-K fusion was identified in 20% (9 of 45) of patients but was not associated with outcome. No BRAF V600E mutations (0 of 40 tested) were found. CONCLUSION: This was the largest single institution series of adult PA. A significant proportion of adult PAs follow an aggressive clinical course. Our results support a period of observation following biopsy or surgical resection. B-K fusion in adult PA does not influence outcome, and BRAF V600E mutation appears to be a very rare event. Further study of tumor biology and optimal treatment is needed, given a more aggressive clinical behavior.
BACKGROUND: Adult pilocytic astrocytomas (PAs) are rare and have an aggressive clinical course compared with pediatric patients. Constitutive Ras/RAF/MAPK signaling appears to be an important oncogenic event in sporadic PA. We evaluated clinical data and molecular profiles of adult PAs at our institution. METHODS: We identified 127 adult PAs in our institutional database. Cases with available tissue were tested for BRAF-KIAA1549 fusion/duplication (B-K fusion) by fluorescence in situ hybridization and submitted for mutation profiling using the Sequenom mutation profiling panel. Subgroup analyses were performed based on clinical and molecular data. RESULTS: The majority of adult PAs are supratentorial. Twenty-two percent of cases had an initial pathologic diagnosis discordant with the diagnosis made at our institution. Recurrence was seen in 42% of cases, and 13% of patients died during follow-up. Adjuvant radiotherapy following surgical resection was associated with a statistically significant decrease in progression-free survival (P = .004). B-K fusion was identified in 20% (9 of 45) of patients but was not associated with outcome. No BRAFV600E mutations (0 of 40 tested) were found. CONCLUSION: This was the largest single institution series of adult PA. A significant proportion of adult PAs follow an aggressive clinical course. Our results support a period of observation following biopsy or surgical resection. B-K fusion in adult PA does not influence outcome, and BRAFV600E mutation appears to be a very rare event. Further study of tumor biology and optimal treatment is needed, given a more aggressive clinical behavior.
Authors: Keita Terashima; Kevin Chow; Jeremy Jones; Charlotte Ahern; Eunji Jo; Benjamin Ellezam; Arnold C Paulino; M Fatih Okcu; Jack Su; Adekunle Adesina; Anita Mahajan; Robert Dauser; William Whitehead; Ching Lau; Murali Chintagumpala Journal: Cancer Date: 2013-04-26 Impact factor: 6.860
Authors: Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway Journal: Nat Genet Date: 2007-02-11 Impact factor: 38.330
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Christoph Burkhard; Pier-Luigi Di Patre; Danielle Schüler; Georges Schüler; M Gazi Yaşargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki Journal: J Neurosurg Date: 2003-06 Impact factor: 5.115
Authors: Carsten Stüer; Belinda Vilz; Michael Majores; Albert Becker; Johannes Schramm; Matthias Simon Journal: Cancer Date: 2007-12-15 Impact factor: 6.860
Authors: Joseph L Wiemels; John K Wiencke; Joseph Patoka; Michelle Moghadassi; Terri Chew; Alex McMillan; Rei Miike; Geoffrey Barger; Margaret Wrensch Journal: Cancer Res Date: 2004-11-15 Impact factor: 12.701
Authors: Sridharan Gururangan; Michael J Fisher; Jeffrey C Allen; James E Herndon; Jennifer A Quinn; David A Reardon; James J Vredenburgh; Annick Desjardins; Peter C Phillips; Melody A Watral; Jeanne M Krauser; Allan H Friedman; Henry S Friedman Journal: Neuro Oncol Date: 2007-03-08 Impact factor: 12.300
Authors: Jacopo Falco; Julius Höhne; Morgan Broggi; Emanuele Rubiu; Francesco Restelli; Ignazio G Vetrano; Marco Schiariti; Elio Mazzapicchi; Giulio Bonomo; Paolo Ferroli; Karl-Michael Schebesch; Francesco Acerbi Journal: Front Oncol Date: 2022-08-09 Impact factor: 5.738
Authors: Adam M Fontebasso; Margret Shirinian; Dong-Anh Khuong-Quang; Denise Bechet; Tenzin Gayden; Marcel Kool; Nicolas De Jay; Karine Jacob; Noha Gerges; Barbara Hutter; Huriye Şeker-Cin; Hendrik Witt; Alexandre Montpetit; Sébastien Brunet; Pierre Lepage; Geneviève Bourret; Almos Klekner; László Bognár; Peter Hauser; Miklós Garami; Jean-Pierre Farmer; Jose-Luis Montes; Jeffrey Atkinson; Sally Lambert; Tony Kwan; Andrey Korshunov; Uri Tabori; V Peter Collins; Steffen Albrecht; Damien Faury; Stefan M Pfister; Werner Paulus; Martin Hasselblatt; David T W Jones; Nada Jabado Journal: Oncotarget Date: 2015-10-13